Biological Evaluation of Medical Devices: Standards, Endpoints, and Testing Strategies

Biological evaluation of medical devices is a risk-based assessment process that verifies the biosafety of materials used in devices that contact patients' bodies, tissues, or blood. Guided primarily by the ISO 10993 series of standards, it encompasses cytotoxicity, sensitization, irritation, genotoxicity, hemocompatibility, and chemical characterization testing performed by accredited third-party laboratories. This article provides a comprehensive technical overview of the evaluation framework, sample categories, required test endpoints, laboratory methods, and practical applications for global regulatory submissions.

Technical Overview

Biological evaluation of medical devices is a systematic, risk-based process designed to identify and quantify potential biological hazards arising from the interaction between device materials and the human body. It forms a mandatory component of pre-market safety documentation for virtually all medical devices that come into direct or indirect contact with patients, whether through skin, mucosal membranes, tissues, or circulating blood.

The internationally recognized framework for this evaluation is the ISO 10993 series, Biological evaluation of medical devices, which defines the selection of biological endpoints based on two fundamental criteria: the nature of body contact and the cumulative duration of contact. In China, the equivalent national standard series is GB/T 16886, which is harmonized with ISO 10993 and is enforced by the National Medical Products Administration (NMPA).

Since the publication of ISO 10993-1:2018, the evaluation philosophy has shifted decisively from a checkbox testing approach toward a holistic risk management process integrated with ISO 14971. Manufacturers are now expected to develop a Biological Evaluation Plan (BEP), leverage material characterization, physical and chemical data, existing clinical and literature evidence, and perform biological testing only when knowledge gaps remain. The outcome is documented in a Biological Evaluation Report (BER), which regulators such as the FDA, European notified bodies under the EU MDR, and the NMPA review during device registration.

Testing Samples

Test sample configuration is determined according to the device categorization defined in ISO 10993-1, which classifies devices by contact type and contact duration. Proper categorization is the first and most critical step, as it dictates which biological endpoints must be addressed.

Surface-Contacting Devices

These devices contact intact skin, intact mucous membranes, or breached or compromised surfaces. Typical examples include electrodes, external prostheses, compression bandages, wound dressings for superficial use, dental impression materials, and examination gloves. For short-duration skin contact, evaluation often focuses on cytotoxicity, sensitization, and irritation or intracutaneous reactivity.

External Communicating Devices

These devices contact tissue, bone, or dentin at points in the communication pathway, or circulate blood indirectly or directly. Examples include infusion sets, extracorporeal circuits, dialyzers, catheters, endoscopes, laparoscopes, and dental cements. Depending on duration, evaluation may extend to systemic toxicity, genotoxicity, hemocompatibility, and implantation effects.

Implant Devices

These devices contact tissue, bone, or blood at the implantation site and remain in place from days to a lifetime. Examples include orthopedic plates, screws and joints, cardiac stents and pacemakers, intraocular lenses, breast implants, absorbable sutures, and dental implants. Long-term implants require the most extensive endpoint set, potentially including subchronic and chronic toxicity, genotoxicity, carcinogenicity, and degradation assessment.

Sample Preparation and Extraction

Test articles are typically evaluated either as the intact device, device portions, or as aqueous and non-aqueous extracts prepared according to ISO 10993-12. Extraction is performed using polar media (such as sodium chloride injection or culture medium) and non-polar media (such as cottonseed oil or sesame oil) under standardized conditions, for example 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour. Extraction ratios are based on device surface area or mass, and exaggerated conditions are justified to simulate worst-case clinical exposure.

Testing Items

ISO 10993-1:2018 defines a matrix of biological endpoints to be considered based on contact category and duration. The core endpoints include:

• Cytotoxicity (ISO 10993-5) — assessment of cell death, inhibition of cell growth, and cytotoxic effects using in vitro mammalian cell culture
• Sensitization (ISO 10993-10) — evaluation of delayed-type hypersensitivity potential
• Irritation and intracutaneous reactivity (ISO 10993-23) — assessment of localized inflammatory responses of skin, eye, or mucosa
• Acute, subacute, and subchronic systemic toxicity (ISO 10993-11) — evaluation of harmful effects following single or repeated exposure
• Genotoxicity (ISO 10993-3) — bacterial reverse mutation assay, chromosomal aberration assay, and mouse lymphoma assay to detect DNA damage
• Hemocompatibility (ISO 10993-4) — hemolysis, thrombogenicity, coagulation, complement activation, and blood cell interactions for blood-contacting devices
• Implantation effects (ISO 10993-6) — local tissue response at the implantation site over defined periods
• Carcinogenicity (ISO 10993-3) — long-term oncogenicity testing when a tumorigenic risk cannot be excluded by other means
• Reproductive and developmental toxicity (ISO 10993-3) — required for devices with relevant exposure pathways or target populations
• Material-mediated pyrogenicity (ISO 10993-11) — assessment of non-endotoxin fever-inducing substances
• Chemical characterization (ISO 10993-18) — identification and quantification of extractables and leachables, including additives, monomers, degradation products, and residuals
• Toxicological risk assessment (ISO 10993-17) — establishment of permissible exposure limits and safety margin calculations
• Sterilization residuals (ISO 10993-7) — quantification of ethylene oxide and its reaction products
• Degradation studies (ISO 10993-9, -13, -14, -15) — characterization of degradation products for absorbable or corroding materials

Testing Methods

In Vitro Cytotoxicity Methods

The most commonly applied technique is the extract (elution) method using mammalian cell lines such as L929 mouse fibroblasts or V79 cells, in which cells are exposed to device extracts and evaluated for viability using qualitative microscopy or quantitative assays such as MTT, neutral red uptake, or colony formation. Direct contact and agar diffusion (overlay) methods are alternatives for specific device geometries. A viability result below 70% of the negative control indicates a cytotoxic effect per ISO 10993-5.

Sensitization and Irritation Testing

Sensitization has traditionally been performed using the guinea pig maximization test (GPMT) or the Buehler test, while the murine local lymph node assay (LLNA) is increasingly favored as a refinement consistent with the 3Rs principles. Irritation and intracutaneous reactivity testing in rabbits involves intradermal or topical application of extracts with scoring of erythema and edema. Validated in vitro reconstructed human epidermis models are now accepted alternatives for skin irritation screening under ISO 10993-23.

Systemic Toxicity and Implantation Studies

Acute systemic toxicity is assessed via single-dose administration of extracts through intravenous or intraperitoneal routes in mice or rats, followed by observation periods defined in ISO 10993-11. Implantation testing places test and control material samples in paravertebral muscle, subcutaneous tissue, or bone of rabbits or rats, with histopathological examination of the surrounding tissue at time points such as 1, 4, 12, 26, or 52 weeks to compare inflammatory responses.

Hemocompatibility Testing

Blood-contacting devices are evaluated for hemolysis using either the direct contact or extract method with incubated human or rabbit blood and spectrophotometric measurement of released hemoglobin. Complement activation is quantified by ELISA measurement of C3a and SC5b-9 markers, while coagulation assays (partial thromboplastin time, prothrombin time) and thrombogenicity assays using dynamic flow models or in vivo venous loops complete the hemocompatibility assessment.

Analytical Chemistry and Risk Assessment

Chemical characterization per ISO 10993-18 employs gas chromatography–mass spectrometry (GC-MS), liquid chromatography–tandem mass spectrometry (LC-MS/MS), inductively coupled plasma mass spectrometry (ICP-MS) and optical emission spectrometry (ICP-OES), infrared spectroscopy (FTIR), and total organic carbon analysis to identify extractable substances. Identified compounds are then evaluated through a toxicological risk assessment per ISO 10993-17, comparing patient exposure against health-based exposure limits derived from authoritative toxicological databases. This chemistry-first approach frequently allows manufacturers to waive certain animal tests with scientific justification.

Applications

Biological evaluation data underpin regulatory submissions across all major markets, including FDA 510(k) and PMA applications in the United States, technical documentation for CE marking under the European Medical Device Regulation (EU) 2017/745, and NMPA registration dossiers in China referencing GB/T 16886. Beyond initial market entry, biological evaluation supports:

• Qualification of new raw material suppliers and material substitution studies
• Assessment of manufacturing, assembly, or sterilization process changes
• Verification of sterilization method effects, including ethylene oxide residual monitoring
• Safety assessment for extended-use or new-indication claims
• Orthopedic implants, cardiovascular stents and catheters, dental materials, wound care products, infusion and transfusion sets, contact lenses, anaesthesia circuits, surgical meshes, and dermal fillers
• Re-evaluation triggered by post-market safety signals, standards updates, or adverse event investigation

Accredited third-party laboratories with GLP-compliant facilities and ISO/IEC 17025 accreditation are typically engaged to perform these studies, ensuring that generated data meets the evidentiary expectations of global regulators.

FAQ

What is the difference between ISO 10993-1 and the rest of the ISO 10993 series?

ISO 10993-1 is the umbrella standard that defines the risk-based evaluation framework and the endpoint selection matrix based on contact nature and duration. The remaining parts of the series provide specific test methodology guidance for individual endpoints, such as ISO 10993-5 for cytotoxicity or ISO 10993-18 for chemical characterization.

How do I determine which biological tests my device requires?

Begin by categorizing the device according to body contact type (surface, external communicating, or implant) and contact duration (limited, prolonged, or long-term), then consult the endpoint matrix in ISO 10993-1:2018. A documented gap analysis, supported by material data and literature review within a Biological Evaluation Plan, determines which endpoints require actual testing versus justification by existing evidence.

Can chemical characterization replace animal testing?

In many cases, yes. Robust extractables and leachables characterization combined with a toxicological risk assessment per ISO 10993-17 and ISO 10993-18 can justify waiving endpoint-specific animal studies such as subchronic toxicity or genotoxicity, provided all identified compounds are below established safety thresholds. Regulators actively encourage this approach under the 3Rs principle of reducing, refining, and replacing animal use.

How long does a complete biological evaluation take?

Timeline varies significantly by endpoint: in vitro cytotoxicity typically completes within two to four weeks, sensitization and irritation studies require approximately six to ten weeks, while implantation and chronic studies may extend from several months to over a year. Chemistry and risk assessment workflows generally require eight to sixteen weeks. A phased evaluation plan aligned with the product development schedule is recommended.

When must biological evaluation be re-performed?

Re-evaluation is required following changes to device materials, formulation, manufacturing processes, sterilization methods, primary packaging, or intended use. The impact assessment should be documented and may conclude that no new testing is needed, that targeted testing is sufficient, or that a full re-evaluation is necessary.